Table 1.
Top 10 enriched pathways in prostate cancer. Pathway analysis of 108 significantly differentially expressed proteins from prostate cancer was carried out using FunRich.
| No. | Pathway | Number of Proteins from the Dataset |
Proteins from Background Dataset |
p-Value | FDR p-Value |
Altered Proteins from the Dataset |
|---|---|---|---|---|---|---|
| 1 | Smooth muscle contraction | 3 | 24 | 0.0001 | 0.1999 | CALD1; MYL6; TPM4 |
| 2 | Muscle contraction | 3 | 50 | 0.0011 | 1 | CALD1; MYL6; TPM4 |
| 3 | Epithelial-to-mesenchymal transition | 3 | 185 | 0.0396 | 1 | PTGDS; CALD1; TAGLN |
| 4 | Semaphorin interactions | 2 | 64 | 0.0283 | 1 | MYL6; HSP90AA1 |
| 5 | Endosomal sorting complex required for transport (ESCRT) | 2 | 28 | 0.0058 | 1 | CHMP4C; CHMP2B |
| 6 | Membrane trafficking | 2 | 84 | 0.0466 | 1 | CHMP4C; CHMP2B |
| 7 | Integrin family cell surface interactions | 7 | 1375 | 0.3354 | 1 | TGM2; STMN1; HSP90AA1; BAIAP2; LAMA2; HMGB1; TAGLN |
| 8 | IFN-gamma pathway | 4 | 1293 | 0.8127 | 1 | STMN1; HSP90AA1; BAIAP2; TAGLN |
| 9 | Syndecan-1-mediated signaling events | 4 | 1297 | 0.8148 | 1 | STMN1; HSP90AA1; BAIAP2; TAGLN |
| 10 | Regulation of CDC42 activity | 3 | 768 | 0.6314 | 1 | STMN1; HSP90AA1; BAIAP2 |